Combination PPAR and RXR Agonist Treatment in Melanoma Cells: Functional Importance of S100A2
Figure 3
Proliferation of A375(DRO) cells overexpressing S100A2. Cells were grown in 2% fetal bovine serum RPMI in the presence of 1 μmol/L of LGD1069, TZD, or the combination for 6 days. Cell growth was analyzed using a nonradioactive cell proliferation assay. Proliferation was compared directly between EV and S100A2 (a) and then to that of cells grown in volume equivalent vehicle (set at 100% which represents cell growth in control conditions) (b). Proliferation was significantly decreased in cells with S100A2 overexpression compared to EV for all treatment conditions compared to control. Columns mean; bars, SEM.